GLSI
Greenwich LifeSciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Greenwich LifeSciences, Inc.
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Greenwich LifeSciences, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Greenwich LifeSciences, Inc.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Jun 1 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Jun 1 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Greenwich LifeSciences, Inc.
16.25
Bull1
Bear2
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $11.4M | 28.80% | +11.98% |
| Vanguardindex-like | $6.5M | 16.49% | −6.73% |
| Geodeindex-like | $3.9M | 9.97% | +8.18% |
| State Streetindex-like | $3.4M | 8.48% | +6.88% |
| Vanguard Portfolioindex-like | $1.9M | 4.79% | +37.26% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $11.4M | 28.80% | +11.98% |
| Vanguardindex-like | $6.5M | 16.49% | −6.73% |
| Geodeindex-like | $3.9M | 9.97% | +8.18% |
| State Streetindex-like | $3.4M | 8.48% | +6.88% |
| Vanguard Portfolioindex-like | $1.9M | 4.79% | +37.26% |
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.